SCHEMBL2011546

SCHEMBL2011546

Nc1ccc2csccc1-2

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.57
TDO2 P48775 1/20 0.46
CYP2A6 P11509 5/20 0.42
GAA P10253 1/20 0.41
IMPDH2 P12268 1/20 0.40
CYP2B6 P20813 3/20 0.39
CYP2E1 P05181 2/20 0.39
LPL P06858 1/20 0.39
LIPG Q9Y5X9 1/20 0.39
MAPT P10636 2/20 0.38
HSD17B10 Q99714 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
USP2 O75604 1/20 0.38
ALOX15 P16050 1/20 0.38
BACE1 P56817 1/20 0.38
CHEK2 O96017 1/20 0.37
ALDH1A1 P00352 2/20 0.37
IKBKB O14920 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5190739 0.82 ALDH1A1 (0.54) KCNH2TDO2CYP2A6GAAIMPDH2
SCHEMBL2009274 0.81 KCNH2 (0.57) KCNH2TDO2CYP2A6GAAIMPDH2
SCHEMBL145993 0.79 KCNH2 (0.55) KCNH2TDO2CYP2A6GAAIMPDH2
Hydrochloric Acid SCHEMBL6740203 0.77 KCNH2 (0.53) KCNH2TDO2CYP2A6GAAIMPDH2
SCHEMBL34467254 0.76 KCNH2 (0.57) KCNH2TDO2CYP2A6GAAIMPDH2
SCHEMBL18516478 0.76 KCNH2 (0.52) KCNH2TDO2CYP2A6GAAIMPDH2
SCHEMBL6255907 0.76 PELI1 (0.53) KCNH2TDO2CYP2A6IMPDH2CYP2B6
SCHEMBL27684579 0.76 KCNH2 (0.52) KCNH2TDO2CYP2A6GAAIMPDH2
SCHEMBL692248 0.74 IMPDH2 (0.54) KCNH2TDO2CYP2A6GAAIMPDH2
SCHEMBL27705236 0.73 CYP2A6 (0.41) KCNH2TDO2CYP2A6GAAIMPDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117903110-A HBV inhibitors and uses thereof 西安新通药物研究股份有限公司 2024-04-19 CN disclosed
CN-114901639-B HBV inhibitors and uses thereof 西安新通药物研究股份有限公司 2023-11-24 CN disclosed
CN-102190661-B Tricyclic benzopyran compound as anti-arrhythmic agents NISSAN CHEMICAL IND LTD 2013-07-31 CN disclosed
US-8394974-B2 Process for producing optically active chromene oxide compound NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2013-03-12 US disclosed
CN-101437827-B Process for producing optically active chromene oxide compound NISSAN CHEMICAL IND LTD 2012-08-29 CN disclosed
CN-102190661-A Tricyclic benzopyran compound as anti-arrhythmic agents NISSAN CHEMICAL IND LTD 2011-09-21 CN disclosed
US-7964623-B2 Tricyclic benzopyrane compound NISSAN CHEMICAL INDUSTRIES LTD. (JP) 2011-06-21 US disclosed
US-20100081808-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2010-04-01 US disclosed
US-20100069374-A1 Tricyclic benzopyrane compound NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2010-03-18 US disclosed
CN-101636392-A Process for production of optically active epoxy compound NISSAN CHEMICAL IND LTD 2010-01-27 CN disclosed
EP-2133343-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND Nissan Chemical Industries, Ltd. (JP) 2009-12-16 EP disclosed
CN-101437827-A Process for producing optically active chromene oxide compound NISSAN CHEMICAL IND LTD (JP) 2009-05-20 CN disclosed
CN-101429200-A Tricyclic benzopyran compound as anti-arrhythmic agents NISSAN CHEMICAL IND LTD (JP) 2009-05-13 CN disclosed
EP-2003135-A9 PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND Nissan Chemical Industries, Ltd. (JP) 2009-04-22 EP disclosed
US-20090043100-A1 Process for Producing Optically Active Chromene Oxide Compound NISSAN CHEMICAL INDUSTRIES, LTD (JP) 2009-02-12 US disclosed
EP-2003135-A2 PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND Nissan Chemical Industries, Ltd. (JP) 2008-12-17 EP disclosed
US-20080004262-A1 Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2008-01-03 US disclosed
CN-1934116-A Tricyclic benzopyran compounds useful as antiarrhythmic agents NISSAN CHEMICAL IND LTD (JP) 2007-03-21 CN disclosed
EP-1732929-A1 TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS Nissan Chemical Industries, Ltd. (JP) 2006-12-20 EP disclosed
WO-2005090357-A1 TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2005-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069374-A1 Tricyclic benzopyrane compound CBR1, CBR3, CYP2C9 KCNH2 28/4885TDO2 543/4885CYP2A6 211/4885
US-20100081808-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND OSTC, EEF1D, SQLE KCNH2 3096/4885TDO2 1439/4885CYP2A6 1204/4885
US-20090043100-A1 Process for Producing Optically Active Chromene Oxide Compound CYP2C19, CYP2C9, CYP1A2 KCNH2 152/4885TDO2 12/4885CYP2A6 76/4885
US-20080004262-A1 Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents CBR1, CBR3, SCN8A KCNH2 21/4885TDO2 632/4885CYP2A6 219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.